{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:44:06Z","timestamp":1793321046372,"version":"4.5.0"},"reference-count":163,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ncl.2023.06.009","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T15:14:11Z","timestamp":1691421251000},"page":"77-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Updates in NMOSD and MOGAD Diagnosis and Treatment"],"prefix":"10.1016","volume":"42","author":[{"given":"Laura","family":"Cacciaguerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O'Connor","year":"2007","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ncl.2023.06.009_bib5","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1001\/jamaneurol.2020.2743","article-title":"Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2023.06.009_bib6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2023.06.009_bib8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'Connell","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.ncl.2023.06.009_bib9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"de Mol","year":"2020","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.ncl.2023.06.009_bib10","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib13","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2023.06.009_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2023.06.009_bib15","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib16","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"20","key":"10.1016\/j.ncl.2023.06.009_bib17","doi-asserted-by":"crossref","first-page":"e1867","DOI":"10.1212\/WNL.0000000000008479","article-title":"Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases","volume":"93","author":"Mariotto","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/jnnp-2021-326779","article-title":"Frequency of MOG-IgG in cerebrospinal fluid versus serum","volume":"93","author":"Pace","year":"2022","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib19","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001095","article-title":"Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability","volume":"9","author":"Kwon","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.ncl.2023.06.009_bib20","doi-asserted-by":"crossref","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","article-title":"Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study","volume":"100","author":"Carta","year":"2023","journal-title":"Neurology"},{"issue":"Pt 7","key":"10.1016\/j.ncl.2023.06.009_bib21","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A\u00a0role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ncl.2023.06.009_bib22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Hoftberger","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1016\/j.ncl.2023.06.009_bib23","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2023.06.009_bib25","doi-asserted-by":"crossref","first-page":"1014071","DOI":"10.3389\/fnins.2023.1014071","article-title":"Complement-dependent cytotoxicity of human autoantibodies against myelin oligodendrocyte glycoprotein","volume":"17","author":"Kohyama","year":"2023","journal-title":"Front Neurosci"},{"key":"10.1016\/j.ncl.2023.06.009_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165373","article-title":"MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity","author":"Yandamuri","year":"2023","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ana.26226","article-title":"Complement Activation Is a Prominent Feature of MOGAD","volume":"90","author":"Keller","year":"2021","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2023.06.009_bib28","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/brain\/awab105","article-title":"Features of MOG required for recognition by patients with MOG antibody-associated disorders","volume":"144","author":"Macrini","year":"2021","journal-title":"Brain"},{"issue":"13","key":"10.1016\/j.ncl.2023.06.009_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300648120","article-title":"Dissection of complement and Fc-receptor-mediated pathomechanisms of autoantibodies to myelin oligodendrocyte glycoprotein","volume":"120","author":"Mader","year":"2023","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"9","key":"10.1016\/j.ncl.2023.06.009_bib30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.ncl.2023.06.009_bib31","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2023.06.009_bib32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib33","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"issue":"10","key":"10.1016\/j.ncl.2023.06.009_bib35","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ncl.2023.06.009_bib36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib37","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/01.wnl.0000224757.69746.fb","article-title":"The clinical features, MRI findings, and outcome of optic neuritis in children","volume":"67","author":"Wilejto","year":"2006","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2023.06.009_bib38","doi-asserted-by":"crossref","first-page":"e1912732","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease","volume":"2","author":"Mariano","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib39","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2023.06.009_bib40","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1136\/jnnp-2013-306573.175","article-title":"How often does respiratory failure occur in neuromyelitis optica?","volume":"84","author":"Elsone","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"13","key":"10.1016\/j.ncl.2023.06.009_bib41","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1212\/WNL.0000000000012599","article-title":"CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies","volume":"97","author":"Zhao-Fleming","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1352458512457720","article-title":"Neuropathic pruritus (itch) in neuromyelitis optica","volume":"19","author":"Elsone","year":"2013","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1001\/archneurol.2011.832","article-title":"Association between paroxysmal tonic spasms and neuromyelitis optica","volume":"69","author":"Usmani","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2023.06.009_bib44","article-title":"Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS","author":"Banks","year":"2020","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaneurol.2016.5441","article-title":"Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder","volume":"74","author":"Dubey","year":"2017","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.ncl.2023.06.009_bib46","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib47","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s13760-021-01792-1","article-title":"Frequency of diencephalic syndrome in NMOSD","volume":"122","author":"Etemadifar","year":"2022","journal-title":"Acta Neurol Belg"},{"issue":"8","key":"10.1016\/j.ncl.2023.06.009_bib48","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/01.wnl.0000343001.36493.ae","article-title":"Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders","volume":"72","author":"Magana","year":"2009","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1212\/01.wnl.0000314832.24682.c6","article-title":"CNS aquaporin-4 autoimmunity in children","volume":"71","author":"McKeon","year":"2008","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2023.06.009_bib50","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib51","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200066","article-title":"Impaired Brain Growth in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Acute Disseminated Encephalomyelitis","volume":"10","author":"Bartels","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0887-8994(03)00143-7","article-title":"Neurocognitive outcome after acute disseminated encephalomyelitis","volume":"29","author":"Hahn","year":"2003","journal-title":"Pediatr Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2023.06.009_bib53","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/87565641.2012.690799","article-title":"Cognitive and behavioral outcomes in individuals with a history of acute disseminated encephalomyelitis (ADEM)","volume":"37","author":"Kuni","year":"2012","journal-title":"Dev Neuropsychol"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ana.26549","article-title":"Cerebral Cortical Encephalitis in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease","volume":"93","author":"Valencia-Sanchez","year":"2023","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib55","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ncl.2023.06.009_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102283","article-title":"FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis With Seizures (FLAMES): Is immunotherapy always needed to put out the fire?","volume":"44","author":"Budhram","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1016\/j.ncl.2023.06.009_bib57","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3174\/ajnr.A5663","article-title":"Imaging Differences between Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis: A Multi-Institutional Study in Japan","volume":"39","author":"Tatekawa","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/13524585211011450","article-title":"Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder","volume":"28","author":"Tajfirouz","year":"2022","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib59","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J\u00a0Neuroinflammation"},{"issue":"8","key":"10.1016\/j.ncl.2023.06.009_bib60","doi-asserted-by":"crossref","first-page":"e851","DOI":"10.1212\/WNL.0000000000200838","article-title":"Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD","volume":"99","author":"Shah","year":"2022","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2023.06.009_bib61","first-page":"1215","article-title":"Asymptomatic Optic Nerve Enhancement in Myelin Oligodendrocyte Glycoprotein Associated Disease","volume":"63","author":"Pacheco","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib62","article-title":"Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis","volume":"4","author":"Srikajon","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib63","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2023.06.009_bib64","doi-asserted-by":"crossref","first-page":"101487","DOI":"10.1016\/j.msard.2019.101487","article-title":"The frequency of longitudinally extensive transverse myelitis in MS: A population-based study","volume":"37","author":"Asnafi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.ncl.2023.06.009_bib65","doi-asserted-by":"crossref","first-page":"e2128871","DOI":"10.1001\/jamanetworkopen.2021.28871","article-title":"Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes","volume":"4","author":"Fadda","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ncl.2023.06.009_bib66","doi-asserted-by":"crossref","first-page":"993645","DOI":"10.3389\/fneur.2022.993645","article-title":"Neuroimaging features in inflammatory myelopathies: A review","volume":"13","author":"Cacciaguerra","year":"2022","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib67","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1212\/NXI.0000000000000343","article-title":"Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder","volume":"4","author":"Asgari","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib68","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1352458520907900","article-title":"Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies","volume":"27","author":"Sechi","year":"2021","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1148\/radiol.2020192664","article-title":"Spinal Cord Atrophy in Neuromyelitis Optica Spectrum Disorders Is Spatially Related to Cord Lesions and Disability","volume":"297","author":"Cacciaguerra","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.ncl.2023.06.009_bib70","doi-asserted-by":"crossref","first-page":"120687","DOI":"10.1016\/j.jns.2023.120687","article-title":"Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS","volume":"450","author":"Webb","year":"2023","journal-title":"J\u00a0Neurol Sci"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib71","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1177\/13524585211060326","article-title":"Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD","volume":"28","author":"Hyun","year":"2022","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.ncl.2023.06.009_bib72","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/jnnp-2014-309761","article-title":"Bright spotty lesions on the spinal cord: an additional MRI indicator of neuromyelitis optica spectrum disorder?","volume":"86","author":"Hyun","year":"2015","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458513495581","article-title":"\"Bright spotty lesions\" on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis","volume":"20","author":"Yonezu","year":"2014","journal-title":"Mult Scler"},{"issue":"14","key":"10.1016\/j.ncl.2023.06.009_bib74","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1177\/1352458518815596","article-title":"Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity","volume":"25","author":"Chien","year":"2019","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib75","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ana.25411","article-title":"Brain and cord imaging features in neuromyelitis optica spectrum disorders","volume":"85","author":"Cacciaguerra","year":"2019","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2023.06.009_bib76","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib77","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/13524585221150743","article-title":"Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis","volume":"29","author":"Chia","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2023.06.009_bib78","article-title":"Cerebral enhancement in MOG antibody-associated disease","author":"Elsbernd","year":"2023","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2023.06.009_bib79","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.msard.2019.04.019","article-title":"Callosal lesions on magnetic resonance imaging with multiple sclerosis, neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis","volume":"32","author":"Cai","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"10.1016\/j.ncl.2023.06.009_bib80","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1212\/WNL.0000000000010662","article-title":"Bilateral extensive corticospinal tract lesions in MOG antibody-associated disease","volume":"95","author":"Mastrangelo","year":"2020","journal-title":"Neurology"},{"issue":"13","key":"10.1016\/j.ncl.2023.06.009_bib81","doi-asserted-by":"crossref","first-page":"e1418","DOI":"10.1212\/WNL.0000000000206820","article-title":"Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder","volume":"100","author":"Cacciaguerra","year":"2023","journal-title":"Neurology"},{"issue":"21","key":"10.1016\/j.ncl.2023.06.009_bib82","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2023.06.009_bib83","doi-asserted-by":"crossref","first-page":"116430","DOI":"10.1016\/j.jns.2019.116430","article-title":"Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study","volume":"405","author":"Chen","year":"2019","journal-title":"J\u00a0Neurol Sci"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib84","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.ncl.2023.06.009_bib85","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders","volume":"75","author":"Lopez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2023.06.009_bib86","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2023.06.009_bib87","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/1352458508094644","article-title":"3D MPRAGE improves classification of cortical lesions in multiple sclerosis","volume":"14","author":"Nelson","year":"2008","journal-title":"Mult Scler"},{"issue":"16","key":"10.1016\/j.ncl.2023.06.009_bib88","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1212\/WNL.0b013e31826e9a96","article-title":"No MRI evidence of cortical lesions in neuromyelitis optica","volume":"79","author":"Calabrese","year":"2012","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2023.06.009_bib89","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1212\/WNL.0b013e3182648bc8","article-title":"Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis","volume":"79","author":"Sinnecker","year":"2012","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2023.06.009_bib90","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1111\/j.1468-1331.2012.03667.x","article-title":"Cortical and leptomeningeal involvement in three cases of neuromyelitis optica","volume":"19","author":"Tahara","year":"2012","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib91","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3988\/jcn.2016.12.2.188","article-title":"Cerebral Cortex Involvement in Neuromyelitis Optica Spectrum Disorder","volume":"12","author":"Kim","year":"2016","journal-title":"J\u00a0Clin Neurol"},{"key":"10.1016\/j.ncl.2023.06.009_bib92","doi-asserted-by":"crossref","DOI":"10.1177\/13524585231166834","article-title":"Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS","author":"Redenbaugh","year":"2023","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.ncl.2023.06.009_bib93","doi-asserted-by":"crossref","first-page":"e1097","DOI":"10.1212\/WNL.0000000000012467","article-title":"Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2023.06.009_bib94","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207478","article-title":"Timing and Predictors of T2-Lesion Resolution in Patients With Myelin-Oligodendrocyte-Glycoprotein-Antibody-Associated Disease","author":"Cacciaguerra","year":"2023","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib95","article-title":"Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders","volume":"7","author":"Redenbaugh","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"9","key":"10.1016\/j.ncl.2023.06.009_bib96","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1177\/1352458514531087","article-title":"Magnetic resonance imaging in neuromyelitis optica","volume":"20","author":"Tackley","year":"2014","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.ncl.2023.06.009_bib97","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(13)70103-0","article-title":"MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials","volume":"12","author":"Sormani","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2023.06.009_bib98","doi-asserted-by":"crossref","first-page":"104215","DOI":"10.1016\/j.msard.2022.104215","article-title":"Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD","volume":"68","author":"Paolilo","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"23","key":"10.1016\/j.ncl.2023.06.009_bib99","doi-asserted-by":"crossref","first-page":"e3124","DOI":"10.1212\/WNL.0000000000010847","article-title":"Incidence of interattack asymptomatic brain lesions in NMO spectrum disorder","volume":"95","author":"Lee","year":"2020","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2023.06.009_bib100","doi-asserted-by":"crossref","first-page":"e2137833","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"18","key":"10.1016\/j.ncl.2023.06.009_bib101","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.0000000000201263","article-title":"Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease","volume":"99","author":"S","year":"2022","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib102","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.25957","article-title":"Silent New Brain MRI Lesions in Children with MOG-Antibody Associated Disease","volume":"89","author":"Fadda","year":"2021","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2023.06.009_bib103","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis Optica Spectrum Disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ncl.2023.06.009_bib104","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2023.06.009_bib105","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD","volume":"10","author":"Prain","year":"2019","journal-title":"Front Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2023.06.009_bib106","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib107","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000674","article-title":"International multicenter examination of MOG antibody assays","volume":"7","author":"Reindl","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ncl.2023.06.009_bib108","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26722","article-title":"Alterations in aquaporin-4-IgG serostatus in 986 patients: a laboratory-based longitudinal analysis","author":"Majed","year":"2023","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.ncl.2023.06.009_bib109","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/WNL.0b013e318211c379","article-title":"CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG","volume":"76","author":"McKeon","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event","volume":"349","author":"Berger","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib111","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1056\/NEJMoa063602","article-title":"Lack of association between antimyelin antibodies and progression to multiple sclerosis","volume":"356","author":"Kuhle","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ncl.2023.06.009_bib112","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/01.WNL.0000127615.15768.AE","article-title":"Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects","volume":"62","author":"Lampasona","year":"2004","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2023.06.009_bib113","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/1352458510376406","article-title":"Serum antibodies to conformational and linear epitopes of myelin oligodendrocyte glycoprotein are not elevated in the preclinical phase of multiple sclerosis","volume":"16","author":"Chan","year":"2010","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.ncl.2023.06.009_bib114","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1177\/1352458514566666","article-title":"Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort","volume":"21","author":"Ketelslegers","year":"2015","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib115","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib116","article-title":"Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients","volume":"7","author":"Held","year":"2021","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib117","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ana.26502","article-title":"MOG and AQP4 Antibodies among Children with Multiple Sclerosis and Controls","volume":"93","author":"Gaudioso","year":"2023","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib118","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1212\/WNL.0000000000012175","article-title":"Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder","volume":"97","author":"Akaishi","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2023.06.009_bib119","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awad122","article-title":"Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids","author":"Matsumoto","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib121","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12974-020-01825-1","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib122","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1\u20132","key":"10.1016\/j.ncl.2023.06.009_bib123","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2023.06.009_bib124","doi-asserted-by":"crossref","first-page":"102638","DOI":"10.1016\/j.msard.2020.102638","article-title":"Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder","volume":"47","author":"Sechi","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.ncl.2023.06.009_bib125","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","article-title":"Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude","volume":"84","author":"Dobson","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib126","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/mus.21197","article-title":"Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica","volume":"39","author":"McKeon","year":"2009","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib127","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/1352458520933884","article-title":"Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD","volume":"27","author":"Kunchok","year":"2021","journal-title":"Mult Scler"},{"issue":"20","key":"10.1016\/j.ncl.2023.06.009_bib128","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib129","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jamaneurol.2019.3656","article-title":"Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib130","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2023.06.009_bib131","doi-asserted-by":"crossref","first-page":"102742","DOI":"10.1016\/j.msard.2021.102742","article-title":"What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM)","volume":"49","author":"Carnero Contentti","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib132","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib133","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib134","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib135","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib136","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1212\/CON.0000000000001168","article-title":"Neuromyelitis Optica Spectrum Disorders","volume":"28","author":"Costello","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib137","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200065","article-title":"Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD","volume":"10","author":"Nosadini","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.ncl.2023.06.009_bib138","doi-asserted-by":"crossref","first-page":"e055392","DOI":"10.1136\/bmjopen-2021-055392","article-title":"Predictors of relapse in MOG antibody associated disease: a cohort study","volume":"11","author":"Huda","year":"2021","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.ncl.2023.06.009_bib139","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/ene.15355","article-title":"Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder","volume":"29","author":"Huang","year":"2022","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib140","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1215\/15228517-2007-004","article-title":"EBV-associated lymphoproliferative disorder of CNS associated with the use of mycophenolate mofetil","volume":"9","author":"O'Neill","year":"2007","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.ncl.2023.06.009_bib141","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.ncl.2023.06.009_bib142","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.ncl.2023.06.009_bib143","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib144","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib145","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2023.06.009_bib146","doi-asserted-by":"crossref","first-page":"102641","DOI":"10.1016\/j.msard.2020.102641","article-title":"Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial","volume":"47","author":"Palace","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib147","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2023.06.009_bib148","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2023.06.009_bib149","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"issue":"10206","key":"10.1016\/j.ncl.2023.06.009_bib150","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ncl.2023.06.009_bib151","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000978","article-title":"Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder","volume":"8","author":"Marignier","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ncl.2023.06.009_bib152","doi-asserted-by":"crossref","first-page":"103356","DOI":"10.1016\/j.msard.2021.103356","article-title":"AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder","volume":"57","author":"Marignier","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ncl.2023.06.009_bib153","doi-asserted-by":"crossref","first-page":"104321","DOI":"10.1016\/j.ebiom.2022.104321","article-title":"Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2\/3 trial","volume":"86","author":"Bennett","year":"2022","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib154","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/13524585211047223","article-title":"Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for \u2a7e4 years in the N-MOmentum trial","volume":"28","author":"Rensel","year":"2022","journal-title":"Mult Scler"},{"issue":"22","key":"10.1016\/j.ncl.2023.06.009_bib155","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ncl.2023.06.009_bib156","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2023.06.009_bib157","doi-asserted-by":"crossref","first-page":"104025","DOI":"10.1016\/j.msard.2022.104025","article-title":"Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar","volume":"66","author":"Yamamura","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ncl.2023.06.009_bib158","doi-asserted-by":"crossref","first-page":"103310","DOI":"10.1016\/j.msard.2021.103310","article-title":"Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder","volume":"56","author":"Thakolwiboon","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.ncl.2023.06.009_bib159","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/jnnp-2022-330086","article-title":"Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"94","author":"Spagni","year":"2023","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2023.06.009_bib160","doi-asserted-by":"crossref","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2023.06.009_bib161","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2023.06.009_bib162","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2023.06.009_bib163","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of Treating Acute Optic Neuritis With Bioequivalent Oral vs Intravenous Corticosteroids: A Randomized Clinical Trial","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861923000634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861923000634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:25:13Z","timestamp":1760005513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861923000634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":163,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0733861923000634"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2023.06.009","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates in NMOSD and MOGAD Diagnosis and Treatment","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2023.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}